IL122305A0 - Tace polypeptide its production and its use - Google Patents

Tace polypeptide its production and its use

Info

Publication number
IL122305A0
IL122305A0 IL12230596A IL12230596A IL122305A0 IL 122305 A0 IL122305 A0 IL 122305A0 IL 12230596 A IL12230596 A IL 12230596A IL 12230596 A IL12230596 A IL 12230596A IL 122305 A0 IL122305 A0 IL 122305A0
Authority
IL
Israel
Prior art keywords
protease
production
isolated
purified
tace polypeptide
Prior art date
Application number
IL12230596A
Other languages
English (en)
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,345 external-priority patent/US5830742A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL122305A0 publication Critical patent/IL122305A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
IL12230596A 1995-06-08 1996-06-03 Tace polypeptide its production and its use IL122305A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48245895A 1995-06-08 1995-06-08
US50461495A 1995-07-20 1995-07-20
US08/655,345 US5830742A (en) 1995-06-08 1996-05-23 TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en) 1995-06-08 1996-06-03 TNF-α CONVERTING ENZYME

Publications (1)

Publication Number Publication Date
IL122305A0 true IL122305A0 (en) 1998-04-05

Family

ID=27413615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12230596A IL122305A0 (en) 1995-06-08 1996-06-03 Tace polypeptide its production and its use

Country Status (13)

Country Link
EP (1) EP0830130B9 (de)
JP (1) JP4326022B2 (de)
AT (1) ATE274346T1 (de)
AU (1) AU712759C (de)
CA (1) CA2222650C (de)
DE (1) DE69633231T2 (de)
DK (1) DK0830130T3 (de)
ES (1) ES2227598T3 (de)
IL (1) IL122305A0 (de)
NO (1) NO323623B1 (de)
NZ (2) NZ312285A (de)
PT (1) PT830130E (de)
WO (1) WO1996041624A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
EP0912746A2 (de) * 1996-07-12 1999-05-06 Schering Corporation Säugetier - tnf - alpha - konvertase
WO1998031818A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
JP2001514494A (ja) * 1997-02-25 2001-09-11 ザ プロクター アンド ギャンブル カンパニー 新規なジスインテグリンメタロプロテアーゼ、変異体、フラグメントなどの使用
US6551857B2 (en) 1997-04-04 2003-04-22 Elm Technology Corporation Three dimensional structure integrated circuits
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
JP2004503202A (ja) * 1998-02-04 2004-02-05 イミュネックス　コーポレイション 結晶性ＴＮＦ−α変換酵素およびその使用
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (de) 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modulation der EGF Rezeptor Signalübertragung durch Hemmung von TACE oder Amphiregulin
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
AU2007291282B2 (en) * 2006-08-28 2011-10-20 Ares Trading S.A. Process for the purification of Fc-fusion proteins
AU2012213240A1 (en) 2011-02-01 2013-08-15 Cancer Research Technology Limited Anti-TACE antibody molecules and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002756A1 (en) * 1989-08-16 1991-03-07 Cetus Corporation Prohormone cleavage site blocking antibody
JP2930713B2 (ja) * 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
DE59106996D1 (de) * 1990-06-22 1996-01-11 Jens Luedemann Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände.
ATE197646T1 (de) * 1990-08-06 2000-12-15 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
EP0648225A1 (de) * 1992-06-25 1995-04-19 Chiron Corporation Zusammensetzungen zur inhibition der bildung von proteinhormonen und anwendungen davon
AU709054B2 (en) * 1994-03-07 1999-08-19 Chiron Corporation Compositions for the inhibition of TNF formation and uses thereof
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase

Also Published As

Publication number Publication date
DE69633231T2 (de) 2005-08-04
JP4326022B2 (ja) 2009-09-02
NO975438D0 (no) 1997-11-26
WO1996041624A1 (en) 1996-12-27
EP0830130B9 (de) 2004-12-29
NO975438L (no) 1998-02-06
NZ312285A (en) 2001-04-27
NZ510390A (en) 2002-11-26
CA2222650A1 (en) 1996-12-27
MX9709744A (es) 1998-07-31
EP0830130B1 (de) 2004-08-25
AU712759C (en) 2001-08-09
NO323623B1 (no) 2007-06-18
DK0830130T3 (da) 2004-12-20
EP0830130A1 (de) 1998-03-25
CA2222650C (en) 2009-10-13
AU6378196A (en) 1997-01-09
DE69633231D1 (de) 2004-09-30
EP0830130A4 (de) 2000-03-29
PT830130E (pt) 2004-11-30
JP2002515020A (ja) 2002-05-21
AU712759B2 (en) 1999-11-18
ATE274346T1 (de) 2004-09-15
ES2227598T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
IL122305A0 (en) Tace polypeptide its production and its use
DE69033699D1 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
EP1484339A3 (de) Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure
MX9804262A (es) Inhibidores derivados de d-aminoacidos de proteasas de cisteina y serina.
EP1160327A3 (de) Proteolytische Enzyme und ihre Verwendung in Waschmitteln
CA2058935A1 (en) Pharmaceutical compositions and method for treatment using alzheimer's amyloid peptides
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
MX9706069A (es) Nuevos inhibidores de la trombina.
TR199902538T2 (xx) Yeni bile�imler.
CA2215695A1 (en) .beta.-sheet mimetics and use thereof as protease inhibitors
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
ATE238062T1 (de) Hemmung von hiv-infektion
BR9608978A (pt) Inibidor de protease de serina derivado de imidazo [1,5a] piridina composição farmacêutica e utilização do inibidor de protease
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FR2837836B1 (fr) UTILISATION DE LA PROTEINE Maba (FABG1) DE MYCOBACTERIUM TUBERCULOSIS POUR LA CONCEPTION ET LE CRIBLAGE D'ANTIBIOTIQUES
TH20752EX (th) อนุพันธ์เพพไทด์ชนิดใหม่
MX9605037A (es) Inhibidores de factor xa.

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees